Clinical Indications and Efficacy of Colloidal Bismuth Subcitrate

References

• Graham D Y. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989; 96: 615–625
   PubMed Web of Science ®Google Scholar
• Marshall B J, Goodwin C S, Warren J R, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; 2: 1437–1442
   PubMed Web of Science ®Google Scholar
• Lambert J R, Lin S K, Borromeo M, Nicholson L, Korman M G, Hansky J. Eradication of Helicobacter pylori with colloidal bismuth subcitrate/antibiotic combinations [Abstract]. Gastroenterology 1990; 98: A74
   Google Scholar
• Borody T, Cole P, Noonan A, Morgan G. Long-term Campylobacter pylori recurrence post eradication [Abstract]. Gastroenterology 1988; 94: A43
   Web of Science ®Google Scholar
• Goodwin C S, Marshall B J, Blincow E D, Wilson D H, Blackbourn S, Phillips M. Prevention of nitroimidazole resistance of Campylobacter pylori by co-administration of colloidal bismuth sub-citrate. J Clin Pathol 1988; 41: 207–210
   PubMed Web of Science ®Google Scholar
• Lambert J R, Dunn K, Borromeo M, Korman M G, Hansky J. Campylobacter pylori—a role in non-ulcer dyspepsia?. Scand J Gastroenterol 1989; 24: 7–13
   Web of Science ®Google Scholar
• Park Y T, Choi K W. An open endoscopic evaluation of the clinical effectiveness of the potassium di-citrato bismuthate in peptic ulcer diseases. Korean J Gastro 1982; 14: 63–67
   Google Scholar
• Skchard R. Un autre traitement des ulceres gastro-duodenaux (le dicitrato bismuthate tripotassique). Schweiz Rundschau Med 1980; 69: 213–215
   Google Scholar
• Tomecki R, Habiox A, Medrzejewski W. Ocena Kliniczna preparatu De-Nol. Pol Tyg Lek 1984; 39: 1247–1248
   PubMedGoogle Scholar
• Verjans H L. Resultados de um ensaio multicentrica abexto, realizado en Portugal, para avaliar a efi-cacia terapeutica do De-Nol liquido em doentes com ulceracao duodenal. Rev. Gastro 1985; 3: 1–11
   Google Scholar
• Hollanders D. Twice daily tripotassium dicitrato bismuthate in the treatment of duodenal ulceration. Post Grad Med J 1986; 62: 19–21
   PubMed Web of Science ®Google Scholar
• Coughlin G P, Kupa A, Alp M H. The effect of tripotassium di-citrato bismuthate (De-Nol) on the healing of chronic duodenal ulcers. Med J Aust 1977; 1: 294–298
   PubMed Web of Science ®Google Scholar
• Dekker W, Reisma K. Double-blind controlled trial with colloidal bismuth sub-citrate in the treatment of symptomatic duodenal ulcers with special references to blood and urine bismuth levels. Ann Clin Res 1979; 11: 94–97
   PubMedGoogle Scholar
• Glover S C, Cantlay J S, Weir J, Mowat N AG. Oral tripotassium-dicitrato bismuthate in gastric and duodenal ulceration; a double-blind controlled trial. Dig Dis Sci 1983; 28: 13–17
   PubMed Web of Science ®Google Scholar
• Lee S P, Nicholson G I. Increased healing of gastric and duodenal ulcers in a controlled trial using tripotassium dicitrato bismuthate. Med J Aust 1977; 1: 808–812
   PubMed Web of Science ®Google Scholar
• Morales A, Antezana C, Roman I, Hurtado C. Effecto de un derivado del bismuto (De-Nol) en la cicatrizacion de ulceras gastricas y duodenales. Rev Med Chile 1982; 110: 959–963
   Google Scholar
• Shreeve D R. A double blind study of tripotassium dicitrato bismuthate in duodenal ulcer. Postgrad Med J 1975; 51(suppl 5)33–36
   PubMedGoogle Scholar
• Vissoulis C, Bissoulis G, Golfis G, Psimenos G. Endoscopic evaluation of TDB in the treatment of duodenal ulcer. Iatrica Chron 1977; 17: 157–164
   Google Scholar
• Wilson P, Alp M H. Colloidal bismuth subcitrate tablets and placebo in chronic duodenal ulceration; a double-blind randomised trial. Med J Aust 1982; 1: 222–223
   PubMed Web of Science ®Google Scholar
• Martin D F, Hollanders D, May S J, Ravenscroft M M, Tweedle D EF. Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate. Lancet 1981; 1: 7–10
   PubMed Web of Science ®Google Scholar
• Gibinski K, Nowak A, Marlicz K, Depczynska A, Dzieniszewski J. Dicytrynianobizmutan trojpotasowy w leczeniu wrzodu trawiennego i zapobieganiu nawrotowi wrzodu. Pol Tyg Lek 1984; 39: 1547–1550
   PubMedGoogle Scholar
• Lazzaroni M, Petrillo M, De Nicola C, Bianchi-Porro G. DE-NOL liquid and cimetidine twice daily in the treatment of duodenal ulcer. A preliminary study. Br J Clin Pract 1983; 37: 379–381
   PubMedGoogle Scholar
• Bianchi-Porro G, Petrillo M, De Nicola C, Lazzaroni M. A double-blind endoscopic study with DE-NOL tablets and cimetidine for duodenal ulcer. Scand J Gastroenterol 1984; 19: 905–908
   PubMed Web of Science ®Google Scholar
• El-Assiouty I M, Tabl A S, El-Shaikh A. A study on a local acting treatment for peptic ulcer in comparison with an H2-receptor antagonist. J Egypt Med Assoc 1986; 69: 59–66
   Google Scholar
• Salmon P R. Combination treatment: colloidal bismuth subcitrate with H2 antagonists. Digestion 1987; 37(suppl 2)42–46
   PubMedGoogle Scholar
• Chearanai O, Kachintorn U, Plengvanit U. Efficacy of tripotassium dicitrato bismuthate and cimetidine in peptic ulcer disease—a control study of 40 gastric ulcer and 80 duodenal ulcer. J Med Assoc Thai 1987; 70: 176–180
   PubMedGoogle Scholar
• Bianchi-Porro G, Lazzaroni M, Barbara L, et al. Tripotassium dicitrato bismuthate and ranitidine in duodenal ulcer healing and influence on recurrence. Scand J Gastroenterol 1988; 23: 1232–1236
   PubMed Web of Science ®Google Scholar
• Lee F I, Samloff I M, Hardman M. Comparison of tripotassium dicitrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. Lancet 1985; 1: 1299–1302
   PubMed Web of Science ®Google Scholar
• Ward M, Halliday C, Cowen A E. A comparison of colloidal bismuth subcitrate tablets and ranitidine in the treatment of chronic duodenal ulcers. Digestion 1986; 34: 173–177
   PubMed Web of Science ®Google Scholar
• Moshal M G, Spitaels J M, Khan F. Tripotassium dicitrato bismuthate chewing tablets and cimetidine in the treatment of duodenal ulcers. A double blind double-dummy comparative study. S Afr Med J 1981; 60: 420–423
   PubMed Web of Science ®Google Scholar
• Dang Z-D, Wang K-T, Tao J-Y, Zhu L-F, Hu X-E. A clinical trial comparing colloidal bismuth subcitrate (DE-NOL liquid) with sucralfate in the treatment of peptic ulceration. Clin Trials J 1986; 23: 235–241
   Google Scholar
• Lam S K, Lee N W, Koo J. Randomised cross-over trial of tripotassium dicitrato bismuthate versus high dose cimetidine for duodenal ulcers resistant to standard dose of cimetidine. Gut 1984; 25: 703–706
   PubMed Web of Science ®Google Scholar
• Bianchi-Porro G, Parente F, Lazzaroni M. Tripotassium dicitrato bismuthate versus two different dosages of cimetidine in the treatment of resistant duodenal ulcers. Gut 1987; 28: 907–911
   PubMed Web of Science ®Google Scholar
• Coghlan J G, Gilligan D, Humphreys H, et al. Campylobacter pylori and recurrence of duodenal ulcers—a 12 month follow-up study. Lancet 1987; 2: 1109–1111
   PubMed Web of Science ®Google Scholar
• Smith A C, Price A B, Borriello P, Levi A J. A comparison of ranitidine and tripotassium dicitrato bismuthate in relapse rates of duodenal ulcer. The role of Campylobacter pyloridis [Abstract]. Gastro-enterology 1988; 94: A431
   Web of Science ®Google Scholar
• Lambert J R, Borromeo M, Korman M G, Hansky J, Eaves E R. Effect of De-Nol on healing and relapse of duodenal ulcers—the role of Campylobacter pyloridis. Gastroenterology 1987; 92: 1489
   Web of Science ®Google Scholar
• Hamilton I, O'Connor H J, Wood N C, Bradbury I, Axon A TR. Healing and recurrence of duodenal ulcer after treatment with TDB tablets or cimetidine. Gut 1986; 27: 106–110
   PubMed Web of Science ®Google Scholar
• Kang J Y, Piper D W. Cimetidine and colloidal bismuth in treatment of chronic duodenal ulcer. Comparison of initial healing and recurrence after healing. Digestion 1982; 23: 73–79
   PubMed Web of Science ®Google Scholar
• Shreeve D R, Mass H J, Jones P E. Comparison of cimetidine and tripotassium dicitrato bismuthate in healing and relapse of duodenal ulcers. Digestion 1983; 28: 96–101
   PubMed Web of Science ®Google Scholar
• Vantrappen G, Schuurmans P, Rutgeerts P, Janssens J. A comparative study of colloidal bismuth subcitrate and cimetidine on the healing and recurrence of duodenal ulcer. Scand J Gastro-enterol 1982; 17: 23–30
   Web of Science ®Google Scholar
• McLean A J, Byrne A J, Harrison P M, McCarthy P. The choice of ulcer healing agent influences duodenal ulcer relapse rate and long-term outcome. Aust NZ J Med 1985; 15: 367–374
   PubMedGoogle Scholar
• Moshal M G, Gregory M A, Pillag C. Does the duodenal cell ever return to normal? A comparison between treatment with cimetidine and de-Nol. Scand J Gastroenterol 1979; 14(suppl 54)48–51
   Google Scholar
• Borody T J, Cole P, Noonan S, et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust 1989; 151: 431–435
   PubMed Web of Science ®Google Scholar
• Rauws E AJ, Tytgat G NJ. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990; 335: 1233–1235
   PubMed Web of Science ®Google Scholar
• Patchett S, O'Riordan T O, Leen E, Keane C, O'Morain C O. A prospective study of Helicobacter pylori eradication in duodenal ulcer [Abstract]. Gastroenterology 1990; 98: A104
   PubMed Web of Science ®Google Scholar
• George L, Hyland L, Morgan A, et al. Smoking does not contribute to duodenal ulcer relapse after Helicobacter pylori eradication [Abstract]. Gastroentcrology 1990; 98: A48
   Google Scholar
• Guslandi M. Dell'Oca M, Ballarin E. Healing of autonomous duodenal erosions with De-Nol. Gastroenterology 1987; 92: 1419
   Web of Science ®Google Scholar
• Nogueira J R, Santoyo R, Noyola J, Esquivel R F. El tratamiento de la ulcera peptica con subcitrato de hismuto (SCB): estudio multicentrico. Compendium 1982; 2(suppl 1)66–70
   Google Scholar
• Boyes B E, Woolf I L, Wilson R Y, Cowley D J, Dymock I W. Treatment of gastric ulceration with a bismuth preparation. Postgrad Med J 1975; 51(suppl 5)29–33
   Google Scholar
• Glover S C, Cantlay J S, Weir J, Mowat N AG. Oral tripotassium dicitrato bismuthate in gastric and duodenal ulceration. A double blind controlled trial. Dig Dis Sci 1983; 28: 13–17
   PubMed Web of Science ®Google Scholar
• Soltoft J, Iversen T O, Linde N C, Rahbek I, Jacobsen O. Comparison between DE-NOL tablets and cimetidine in the treatment of gastric ulcer. A double-blind multicentre investigation. Ugeskr Laeg 1985; 147: 1850–1851
   Google Scholar
• Shou-Po C, Guo-Zong P. Short-term treatment with colloidal bismuth subcitrate (De-Nol) and cimetidine in Chinese patients with gastric ulcer. Clin Trials 1986; 23: 215–219
   Web of Science ®Google Scholar
• Tytgat G NJ, Van Bentem N, Van Olffen G, Dekker W, Rutgeerts L. Controlled trial comparing colloidal bismuth subcitrate tablets, cimetidine and placebo in the treatment of gastric ulceration. Scand J Gastroenterol 1982; 17(suppl 80)31–38
   Google Scholar
• Parente F, Lazzaroni M, Petrillo M, Bianchi-Porro G. Colloidal bismuth subcitrate and ranitidine in the short-term treatment of benign gastric ulcer. An endoscopically controlled trial. Scand J Gastroenterol 1986; 21(suppl 122)42–45
   Google Scholar
• Cipollini F, Altilia F. Comparison of tripotassium dicitrato bismuthate (TDB) with ranitidine in healing and relapse of gastric ulcer. Br J Clin Pract 1987; 41: 707–709
   PubMedGoogle Scholar
• Dekker W, Baars H, Scuro L A, Cavallini G, Staal J AJ, Vogten A JM. Colloidal bismuth subcitrate and sucralfate in gastric ulcer healing and relapse. Acta Ther 1989; 15: 189–198
   Google Scholar
• Patty I, Tarnok F, Simon L, Javor T, Deak G. A comparative dynamic study of the effectiveness of gastric cytoprotection by Vitamin A, De-Nol, sucralfate and ulcer healing by pirenzepine in patients with chronic gastric ulcer (a multiclinical and randomized study). Acta Physiol Acad Sci Hung 1984; 64: 379–384
   Google Scholar
• Tytgat G NJ. Colloidal bismuth subcitrate in peptic ulcer. A review. Digestion 1987; 37: 31–41
   PubMed Web of Science ®Google Scholar
• Borsch G. Antibacterial therapy: effect on healing and relapse of peptic ulcer disease. Helicobacter pylori gastritis and peptic ulcer, P Malfertheiner, Ditschuneit. Springer-Verlag, Berlin 1990; 441–447
   Google Scholar
• Colin-Jones D G. Management of dyspepsia: report of a working party. Lancet 1988; 1: 579
   Web of Science ®Google Scholar
• Jeena C P, Simjee K E, Pettengall J M. Comparison of symptoms in Campylobacter pylori positive and negative patients presenting with dyspepsia for upper gastrointestinal endoscopy. Afr Med J 1988; 73: 659
   Web of Science ®Google Scholar
• Shallcross T M, Rathbone B J, Heatley R V. Campylobacter pylori and non-ulcer dyspepsia. Campylobacter pylori and gastroduodenal disease, B J Rathbone, R V Heatley. Blackwell Scientific, Oxford 1989; 155–166
   Google Scholar
• Anderson L P, Elsborg L, Justesen T. Campylobacter pylori in peptic ulcer disease. III. Symptoms and paraclinical and epidemiological findings. Scand J Gastroenterol 1988; 23: 347–350
   PubMed Web of Science ®Google Scholar
• Borsch G, Schmidt G, Wegener M. Campylobacter pylori: prospective analysis of clinical and histological factors associated with colonization of the upper gastrointestinal tract. Eur J Clin Invest 1988; 18: 133–138
   PubMed Web of Science ®Google Scholar
• Rauws E AJ, Langenberg W, Houtoff H J, Zanen H C, Tytgat G NJ. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and anti-ulcer treatment. Gastroenterology 1988; 94: 33–40
   PubMed Web of Science ®Google Scholar
• Borody T, Hennessy W, Daskolopoulos G. Double-blind trial of De-Nol in non-ulcer dyspepsia associated with Campylobacter pyloridis gastritis [Abstract]. Gastroenterology 1987; 92: 1324
   Web of Science ®Google Scholar
• Rokkas T, Pursey C, Uzoechina E, et al. Non-ulcer dyspepsia and short-term DE-NOL therapy: a placebo-controlled trial with particular reference to the role of Campylobacter pylori. Gut 1988; 29: 1386–1391
   PubMed Web of Science ®Google Scholar
• Kang J Y, Tay H H, Wee A, Guan R, Math M V, Yap I. The effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia—a double blind placebo controlled study [Abstract]. Gut 1988; 29: A1440
   Web of Science ®Google Scholar
• Loffeld R JLF, Potters H VJP, Stobberingh E, Flendrig J A, Van Spreeuwel J P, Arends J W. Campylobacter associated gastritis in patients with non-ulcer dyspepsia: a double blind placebo-controlled trial with colloidal bismuth subcitrate. Gut 1989; 30: 1206–1212
   PubMed Web of Science ®Google Scholar
• Tasman-Jones C, Maher C, Thomsen L, Lee S P, Vanderwee M. Mucosal defences and gastroduo-denal disease. Digestion 1987; 37(suppl 2)1–7
   PubMedGoogle Scholar
• Konturek S J, Radecki T, Piastucki I, Drozdowicz D. Studies on the gastro-protective and ulcerhealing effects of colloidal bismuth subcitrate. Digestion 1987; 37(suppl 2)8–15
   PubMedGoogle Scholar
• Baron J H, Barr J, Batten J, Sidebotham R, Spencer J. Acid, pepsin and mucus secretion in patients with gastric and duodenal ulcer before and after colloidal bismuth subcitrate (De-Nol). Gut 1986; 27: 486–490
   PubMed Web of Science ®Google Scholar
• Slomiany B L, Bilski J, Sarosiek J, Liau Y H, Slomiany A. Colloidal bismuth subcitrate inhibits peptic degradation of epidermal growth factor [Abstract]. Gastroenterology 1988; 94: A431
   Web of Science ®Google Scholar
• Hardo P G, Giles T E, Kennedy T, Zakhour H, Ferguson R. De-Nol as protection against NSAID-induced mucosal damage?. J Drug Dev 1990; 3: 151–153
   Google Scholar
• Katz B, Lambert J R, Nicholson L, et al. H. pylori infection, upper gastrointestinal symptoms and blood loss in patients with rheumatoid arthritis on NSAID. Gastroenterology 1991, (in press)
   Google Scholar
• Graham D Y, Lidsky M D, Cox A, et al. Helicobacter infection, NSAIDs and the gastroduodenal mucosa [Abstract]. Gastroenterology 1990; 98: A52
   Google Scholar